Enjoy complimentary customisation on priority with our Enterprise License!
The sulphonamides market size is forecast to increase by USD 123.4 million at a CAGR of 4.5% between 2023 and 2028. The market is witnessing significant growth due to the rising prevalence of infectious diseases and increasing awareness of various diseases and their treatment. The market is driven by the high demand for sulphonamides in the pharmaceutical industry for the production of antibiotics, antipyretics, and antiprotozoal agents. However, decreased investments in research activities pose a challenge to the market's growth. Additionally, the emergence of alternative treatments and increasing resistance to sulphonamides among pathogens are other significant challenges. Despite these challenges, the market is expected to grow at a steady pace due to the large patient population suffering from infectious diseases and the effectiveness of sulphonamides in treating various infections.
Sulphonamides are a class of antibiotics widely used in the pharmaceutical industry for the treatment of various bacterial infections. They inhibit folic acid synthesis in bacteria, preventing their growth. Sulphonamides find extensive applications in the treatment of Urinary Tract Infections (UTIs), ulcerative colitis, and Malaria caused by Plasmodium falciparum. Sulfadoxine, a sulphonamide derivative, is used as an antimalarial substance. The market for Sulphonamides is driven by the increasing prevalence of bacterial infections and the growing demand for effective and affordable antibiotics. Cutting-edge technologies like high-throughput, combinatorial chemistry and bioinformatics are being employed to discover new Sulphonamides with improved efficacy and reduced side effects.
Furthermore, sulphonamides are available in various forms, including oral and topical, for the treatment of skin infections, gastrointestinal tract infections, and respiratory tract infections. However, the side effects associated with their use, such as allergic reactions and kidney damage, limit their widespread use. Research and development efforts are focused on developing new Sulphonamides with improved efficacy and reduced side effects, as well as exploring new applications for these antibiotics in areas like Family Welfare and Insecticides. SIMBRINZA, a new Sulphonamide-based drug, is gaining popularity for its effectiveness in treating UTIs.
The market for Sulphonamides is expected to grow steadily in the coming years due to the increasing demand for effective antibiotics and the ongoing research and development efforts in this field.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The oral segment is estimated to witness significant growth during the forecast period. Sulphonamides, a class of antibacterial drugs, have been extensively used in the medical field for the treatment of various bacterial infections, including urinary tract infections (UTIs), gastrointestinal tract infections, and STIs. These drugs are also effective in managing skin conditions such as eczema, alopecia, rosacea, and psoriasis.
Get a glance at the market share of various segments Request Free Sample
The oral segment accounted for USD 307.80 million in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Sulphonamides, a class of antibacterial drugs, have been extensively used in the medical field for the treatment of various bacterial infections, including urinary tract infections (UTIs), gastrointestinal tract infections, and STIs. These drugs are also effective in managing skin conditions such as eczema, alopecia, rosacea, and psoriasis. In the realm of medical research, drug discovery continues to explore potential substitutes for sulfa drugs in light of drug-resistant bacteria and emerging diseases like tuberculosis and NTSS. According to Verywell Health, sulphonamides work by inhibiting the growth of bacteria by interfering with their folic acid metabolism. In the competitive landscape, companies in the market employ business strategies such as product satisfaction, competitive assessment, and intelligence to cater to their customer base.
Furthermore, quadrants like the Forefront, Pathfinder, Niche, Vital, and Customer Base help in understanding the market dynamics and positioning of key players. Despite advancements in alternative treatments, the demand for sulphonamides remains significant due to their efficacy and affordability. In the context of type 2 diabetes, sulphonamides are used to treat bacterial infections that can complicate diabetes management. Overall, the market continues to evolve, driven by the need for effective treatments for bacterial infections and skin conditions.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of infectious diseases is the key driver of the market. The global health landscape is currently grappling with the increasing burden of infectious diseases, which are primarily caused by bacteria, viruses, and parasites. These pathogens thrive in environments that favor their growth and transmission, such as high population densities and urbanization. For instance, deforestation and destruction of natural habitats can bring humans into closer contact with disease-carrying animals and insects. Sulphonamides, a class of antibiotics, have been instrumental in combating various bacterial infections, including Urinary Tract Infections (UTIs) and skin infections. These drugs interfere with Folic acid synthesis in bacteria, inhibiting their growth. However, their use extends beyond antibacterial applications.
For example, sulfonamides like Sulfadoxine are used in the prevention and treatment of malaria, targeting the parasite Plasmodium falciparum. Innovations in cutting-edge technologies such as high-throughput, combinatorial chemistry, and bioinformatics have led to the discovery of new antimalarial substances and SARS-CoV-2 inhibitors. These advancements are crucial in addressing the growing threat of chronic diseases and emerging pathogens. Sulphonamides also find applications in the treatment of eye diseases. For instance, Brimonidine tartrate and brinzolamide, collectively marketed as SIMBRINZA, are used for the treatment of open-angle glaucoma and ocular hypertension. Despite their benefits, sulphonamides can cause side effects, primarily when administered orally or topically.
In addition, common side effects include skin sensations, gastrointestinal tract disturbances, and allergic reactions. The route of administration significantly influences the occurrence and severity of side effects. In summary, sulphonamides have been a vital contribution to the pharmaceutical industry, playing a pivotal role in the treatment and prevention of various infectious diseases, from UTIs and skin infections to malaria and ocular diseases. Continuous research and innovation in bioorganic and medicinal chemistry letters are essential to address the challenges posed by emerging pathogens and chronic diseases while minimizing the side effects of these essential medications.
Growing awareness of various diseases and their treatment is the upcoming trend in the market. Sulphonamides, a crucial class of antibacterial agents, inhibit folic acid synthesis in bacteria, thereby impeding the growth of microorganisms responsible for various infectious diseases. These antibiotics have found extensive applications in the treatment of urinary tract infections (UTIs), ulcerative colitis, and malaria. In malaria, sulfonamides like sulfadoxine are used in combination with pyrimethamine to target Plasmodium falciparum. Moreover, sulfonamides have also been explored as antimalarial substances using cutting-edge technologies such as high-throughput screening, combinatorial chemistry, and bioinformatics. Sulphonamides are also used in the production of insecticides and as antimalarial substances. In the pharmaceutical industry, they are used to develop drugs for chronic diseases such as skin sensations, fungal skin infections, acne, and atopic dermatitis.
Furthermore, Brimonidine tartrate and brinzolamide, marketed under the brand names SIMBRINZA and ALPHAGAN, are sulfonamides used in the treatment of glaucoma. Despite their benefits, sulfonamides have side effects, and the route of administration varies from oral to topical, depending on the condition being treated. Oral sulfonamides are used for gastrointestinal tract infections, while topical sulfonamides are used for skin infections. The side effects and route of administration should be considered when prescribing these drugs. Researchers are also exploring the potential of sulfonamides as SARS-CoV-2 inhibitors, further expanding their therapeutic applications. The Baum laboratory at Imperial College London and Medicinal Chemistry Letters have published research on the use of sulfonamides as potential inhibitors of SARS-CoV-2.
In addition, family welfare programs and awareness campaigns, such as European Antibiotic Awareness Day and World Hand Hygiene Day, promote the judicious use of antibiotics, including sulfonamides, to prevent the development of antibiotic resistance.
Decreased investments in research activities is a key challenge affecting the market growth. The market has witnessed significant advancements in the field of bacterial infections, particularly in the synthesis of folic acid, an essential component for DNA and RNA production in bacteria. However, the development of new sulphonamides has faced challenges due to the decreased investment from pharmaceutical companies. This is primarily due to the high costs and lengthy development process of these drugs, which yield relatively lower profits. Newer sulphonamides, such as those used for ulcerative colitis, malaria treatment with Sulfadoxine, and insecticides, are priced at a maximum of USD 1,000 to USD 3,000 per course. In comparison, other therapeutic areas, like cancer therapy, generate substantial profits.
In addition, cutting-edge technologies, including high throughput, combinatorial chemistry, and bioinformatics, are being employed to discover new antimalarial substances. For instance, researchers at Baum Laboratory, Imperial College London, are developing SIMBRINZA, a novel antimalarial substance. In addition, sulphonamides are being explored as potential SARS-CoV-2 inhibitors, showcasing their potential in chronic diseases treatment. Beyond bacterial infections, sulphonamides are used for various indications, such as skin infections, gastrointestinal tract disorders, urinary tract infections, and respiratory tract infections. In the dermatology field, brimonidine tartrate and brinzolamide, sulphonamide derivatives, are used for treating fungal skin infections, acne, and atopic dermatitis. Despite their benefits, sulphonamides may cause side effects, which can impact their route of administration. They are available in oral and topical forms, and their administration depends on the specific condition being treated.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AA Pharma Inc. - The company offers sulphonamides such as APO Sulftrim, APO Sulfatrim DS.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Sulphonamides are a class of antibacterial drugs that have been widely used in the medical field for several decades. They are primarily used in the synthesis of folic acid, an essential nutrient for bacterial growth, thereby inhibiting bacterial multiplication. Sulphonamides have found applications in various therapeutic areas, including urinary tract infections (UTIs), ulcerative colitis, and malaria. In the context of malaria, sulphonamides have been used in combination with other antimalarial substances to target Plasmodium falciparum, the parasite responsible for the most severe forms of the disease. The development of cutting-edge technologies such as high-throughput, combinatorial chemistry, and bioinformatics has led to the discovery of new sulphonamides with enhanced efficacy and reduced side effects.
Furthermore, sulphonamides have also found applications in the treatment of skin infections, including fungal infections, acne, and atopic dermatitis. The oral and topical routes of administration have been explored for these indications, with Brimonidine tartrate (SIMBRINZA) and brinzolamide being notable examples. However, the use of sulphonamides is not without side effects, and the route of administration can influence their safety profile. For instance, skin sensations and gastrointestinal tract irritation are common side effects of oral sulphonamides, while topical sulphonamides may cause local skin reactions. In the pharmaceutical industry, research on sulphonamides continues to advance, with recent studies exploring their potential as SARS-CoV-2 inhibitors and treatments for chronic diseases.
In addition, the Bioorganic and Medicinal Chemistry Letters and Journal of European Academy of Dermatology and Venereology (JEADV) are among the publications that have reported on the latest developments in this area. In addition, sulphonamides have also found applications as insecticides, particularly in the production of antibiotics. The Baum laboratory at Imperial College London and the work of researchers at the University of California, Berkeley, are among the notable contributions in this area. In conclusion, sulphonamides continue to be an essential class of drugs with diverse applications in various therapeutic areas, from bacterial infections to chronic diseases and insecticides. The ongoing research in this field is expected to yield new discoveries and innovations, further expanding the therapeutic potential of sulphonamides.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
140 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
|
Market growth 2024-2028 |
USD 123.4 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.23 |
|
Regional analysis |
North America, Europe, APAC, South America, and Middle East and Africa |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, China, Germany, France, Canada, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AA Pharma Inc., Abbott Laboratories, Agron Remedies Pvt. Ltd., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Cipla Inc., Dhanuka Agritech Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lexine Technochem Pvt. Ltd., Novartis AG, PANPHARMA S.A., Pfizer Inc., Sanofi SA, Smilax Laboratories Ltd., Stedman Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Formulation
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
